Skip to main content

Table 3 Tumor response

From: Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study

Variable

Total (n = 38)

Best response, n (%)

Complete response

1 (2.6)

Partial response

2 (5.3)

Stable disease

26 (68.4)

Progressive disease

9 (23.7)

Objective response rate, n (%)

3 (7.9)

Disease control rate, n (%)

29 (76.3)

6-month PFS rate, % (95% CI)

59.8 (41.8, 77.8)